




- (51) **International Patent Classification:**
C07K 14/435 (2006.01)
- (21) **International Application Number:**
PCT/US2020/020415
- (22) **International Filing Date:**
28 February 2020 (28.02.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/812,911 01 March 2019 (01.03.2019) US
62/980,823 24 February 2020 (24.02.2020) US
- (71) **Applicant: ALLOGENE THERAPEUTICS, INC.**
[US/US]; 210 E. Grand Avenue, South San Francisco, California 94080 (US).
- (72) **Inventors: LIN, Regina Junhui;** c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **VAN BLARCOM, Thomas John;** c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **PANOWSKI, Siler;** c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **SASU, Bar-**
- bra Johnson;** c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US).
- (74) **Agent: CHANG, Y. Elaine et al.;** Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORS

FIG. 3B



(57) **Abstract:** Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*